Page 1 | Search Results | Blood | American Society of Hematology

1-14 of 14

Sort by

Sort Order Select

Journal Articles

Clonal Hematopoiesis Mutations and Cell-Free DNA Characteristics in Patients with High-Risk Large B-Cell Lymphomas

Miro Nylén, Leo Meriranta, Emil Hiitola, Maare Arffman, Harald Holte, Judit Mészáros Joergensen, Peter Brown, Sirkku Jyrkkiö, Mats Jerkeman, Øystein Fluge, Magnus Björkholm, Lars Møller Pedersen, Mikael Eriksson, Satu Mustjoki, Sirpa Leppä, Mikko Myllymäki

Blood (2024) 144 (Supplement 1): 1601.

https://doi.org/10.1182/blood-2024-201928

Published: 2024

Journal Articles

Joint Analyses of Serum Proteins and Circulating Tumor DNA Improves Risk Assessment and Subtype Stratification in Large B-Cell Lymphomas

Maare Arffman, Leo Meriranta, Judit Mészáros Jørgensen, Harald Holte, Øystein Fluge, Peter de Nully Brown, Kristina Drott, Sirkku Jyrkkiö, Suvi-Katri Leivonen, Sirpa Leppä

Blood (2023) 142 (Supplement 1): 3015.

https://doi.org/10.1182/blood-2023-177849

Published: 2023

Journal Articles

Distinct Genetic and Fragmentomic Signatures of Plasma Ctdna Synergize and Resolve Clinical Challenges in Patients with Large B-Cell Lymphoma

Leo Meriranta, Maare Arffman, Judit Mészáros Jørgensen, Harald Holte, Kristina Drott, Henrikki Almusa, Emma Saarinen, Sari Hannula, Marja-Liisa Karjalainen-Lindsberg, Klaus Beiske, Mette Ølgod Pedersen, Øystein Fluge, Peter de Nully Brown, Sirkku Jyrkkiö, Sirpa Leppä

Blood (2023) 142 (Supplement 1): 1625.

https://doi.org/10.1182/blood-2023-188493

Published: 2023

Journal Articles

Serum Proteome Profiling Reveals Inflammatory, Molecular and Prognostic Information Beyond the Ctdna in Aggressive B-Cell Lymphomas

Maare Arffman, Leo Meriranta, Harald Holte, Judit Jørgensen, Peter De Nully Brown, Sirkku Jyrkkio, Mats Jerkeman, Øystein Fluge, Magnus Björkholm, Matias Autio, Suvi-Katri Leivonen, Sirpa Leppa

Blood (2022) 140 (Supplement 1): 1316–1317.

https://doi.org/10.1182/blood-2022-158426

Published: 2022

Journal Articles

Biomarker-Driven Treatment Strategy in High-Risk Large B-Cell Lymphoma: Final Results of a Nordic Phase 2 Study

Blood (2022) 140 (Supplement 1): 1768–1769.

https://doi.org/10.1182/blood-2022-158183

Published: 2022

Journal Articles

Molecular features encoded in the ctDNA reveal heterogeneity and predict outcome in high-risk aggressive B-cell lymphoma

Blood (2022) 139 (12): 1863–1877.

https://doi.org/10.1182/blood.2021012852

Published: 2022

Includes: Supplemental data

Journal Articles

Dose-Dense Chemoimmunotherapy Including Early CNS Prophylaxis for High-Risk DLBCL. -Final Analysis from a Nordic Phase II Study (the CHIC trial)

Blood (2016) 128 (22): 1854.

https://doi.org/10.1182/blood.V128.22.1854.1854

Published: 2016

Journal Articles

Plasma Affinity Proteomic Immunoprofiling As a Novel Prognostic Tool in High Risk Diffuse Large B-Cell Lymphoma Patients: A Nordic Lymphoma Group Study

Karin Fjordén, MD, Frida Pauly, PhD, Sirpa Leppä, MD PhD, Harald Holte, MD PhD, Magnus Björkholm, MD PhD, Oystein Fluge, MD PhD, Lars Möller Pedersen, MD PhD, Mikael Eriksson, MD PhD, Anna Isinger-Ekstrand, PhD, Carl Borrebaeck, PhD, Mats Jerkeman, MD PhD, Christer Wingren, PhD

Blood (2014) 124 (21): 1618.

https://doi.org/10.1182/blood.V124.21.1618.1618

Published: 2014

Journal Articles

Dose-Dense Chemoimmunotherapy and Early Central Nervous System Prophylaxis For High-Risk Diffuse Large B-Cell Lymphoma. –Preliminary Results From a Nordic Phase II Study

Sirpa Leppa, Anne Maria Tierens, Judit Jorgensen, Mats Jerkeman, Magnus Bjorkholm, PhD, Øystein Fluge, Sirkku Jyrkkio, Harald Holte, MD, PhD

Blood (2013) 122 (21): 849.

https://doi.org/10.1182/blood.V122.21.849.849

Published: 2013

Journal Articles

Age-Adjusted Combined Immunochemotherapy without Radiotherapy in Newly Diagnosed PCNSL – A Phase II Trial of the Nordic Lymphoma Group

Elisa Jacobsen Pulczynski, Peter Kamper, Unn-Merete Fagerli, Martin Erlanson, Outi Kuittinen, Alexander Fosså, Bjørn Østenstad, Oystein Fluge, Martin Maisenhølder, Hans Hagberg, Mikael Eriksson, Marie Nordstrøm, Sirpa Leppa

Blood (2011) 118 (21): 1602.

https://doi.org/10.1182/blood.V118.21.1602.1602

Published: 2011

Journal Articles

High Serum Vascular Endothelial Growth Factor (VEGF) Level Is An Adverse Prognostic Factor In High Risk Diffuse Large B-Cell Lymphoma (DLBCL) Patients Treated with Dose-Dense Chemoimmunotherapy and Systemic CNS Prophylaxis. Results From a Nordic Phase II Study

Sari Riihijarvi, Heidi Nyman, Harald Holte, Magnus Bjorkholm, Oystein Fluge, Lars Moller Pedersen, Mats Jerkeman, Eriksson Mikael, Sirpa Leppa

Blood (2010) 116 (21): 4142.

https://doi.org/10.1182/blood.V116.21.4142.4142

Published: 2010

Journal Articles

R-CHOEP-14 × 6 Followed by Systemic CNS Prophylaxis for Diffuse Large B-Cell Lymphoma/Follicular Lymphoma Grade 3 with Age Adjusted IPI Score 2–3: Final Results of a Nordic Lymphoma Group Phase 2 Study Including 156 Patients Aged 18–65 Years.

Harald Holte, MD, PhD, Sirpa LeppÃ¤, MD, PhD, Magnus Bjorkholm, MD, PhD, Øystein Fluge, MD, PhD, Sirkku Jyrkkiö, MD, PhD, Jan Delabie, MD, PhD, Christer Sundstrom, MD, PhD, Marja-Liisa Karjalainen-Lindsberg, Martin Erlanson, MD, PhD, Arne Kolstad, MD, PhD, Alexander Fosså, MD, PhD, Bj∅rn Østenstad, MD, PhD, Eva Löfvenberg, MD, Marie Nordström, MD, PhD, Lars Möller Pedersen, MD, PhD, Harald Anderson, PhD, Mats Jerkeman, MD, PhD, Mikael Eriksson, MD, PhD

Blood (2010) 116 (21): 2805.

https://doi.org/10.1182/blood.V116.21.2805.2805

Published: 2010

Journal Articles

Exon-Based Transcriptome Profiling Reveals Genes That Have Prognostic Impact on the Survival of Young High Risk Diffuse Large B-Cell/Follicular Grade 3 Lymphoma Patients Treated with Dose-Dense Chemoimmunotherapy and CNS Prophylaxis. Results From a Nordic Lymphoma Group Phase II Study

Satu Koivula, Minna Taskinen, Ping Chen, Harald Holte, Jan Delabie, Marja-Liisa Karjalainen-Lindsberg, Magnus Bjorkholm, Oystein Fluge, Lars Moller Pedersen, Mats Jerkeman, Mikael Eriksson, Sampsa Hautaniemi, Sirpa Leppa

Blood (2010) 116 (21): 3107.

https://doi.org/10.1182/blood.V116.21.3107.3107

Published: 2010

Journal Articles

R-CHOEP-14 X 6 Followed by Systemic CNS Prophylaxis for Diffuse Large B-Cell Lymphoma (DLBCL)/Follicular Lymphoma (FL) Grade 3 with Age Adjusted IPI Score 2–3: Preliminary Results of a Nordic Lymphoma Group (NLG) Phase 2 Study Including 160 Patients Aged 18- 64 Years

Harald Holte, MD, PhD, Sirpa M. Leppa, MD, PhD, Magnus Bjorkholm, MD, PhD, Oystein Fluge, MD, PhD, Sirkku Jyrkkio, MD, PhD, Jan Delabie, MD, PhD, Christer Sundstrom, MD, PhD, Marja-Liisa Karjalainen-Lindsberg, MD, PhD, Martin Erlanson, MD, PhD, Arne Kolstad, MD, PhD, Alexander Fossa, MD, PhD, Björn Östenstad, MD, PhD, Eva Lofvenberg, MD, PhD, Marie Nordström, MD, PhD, Lars Möller-Pedersen, MD, PhD, Harald Anderson, PhD, Mats Jerkeman, MD, PhD, Mikael Eriksson, MD, PhD

Blood (2008) 112 (11): 3604.

https://doi.org/10.1182/blood.V112.11.3604.3604

Published: 2008

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Clonal Hematopoiesis Mutations and Cell-Free DNA Characteristics in Patients with High-Risk Large B-Cell Lymphomas

Joint Analyses of Serum Proteins and Circulating Tumor DNA Improves Risk Assessment and Subtype Stratification in Large B-Cell Lymphomas

Distinct Genetic and Fragmentomic Signatures of Plasma Ctdna Synergize and Resolve Clinical Challenges in Patients with Large B-Cell Lymphoma

Serum Proteome Profiling Reveals Inflammatory, Molecular and Prognostic Information Beyond the Ctdna in Aggressive B-Cell Lymphomas

Biomarker-Driven Treatment Strategy in High-Risk Large B-Cell Lymphoma: Final Results of a Nordic Phase 2 Study

Molecular features encoded in the ctDNA reveal heterogeneity and predict outcome in high-risk aggressive B-cell lymphoma

Dose-Dense Chemoimmunotherapy Including Early CNS Prophylaxis for High-Risk DLBCL. -Final Analysis from a Nordic Phase II Study (the CHIC trial)

Plasma Affinity Proteomic Immunoprofiling As a Novel Prognostic Tool in High Risk Diffuse Large B-Cell Lymphoma Patients: A Nordic Lymphoma Group Study

Dose-Dense Chemoimmunotherapy and Early Central Nervous System Prophylaxis For High-Risk Diffuse Large B-Cell Lymphoma. –Preliminary Results From a Nordic Phase II Study

Age-Adjusted Combined Immunochemotherapy without Radiotherapy in Newly Diagnosed PCNSL – A Phase II Trial of the Nordic Lymphoma Group

High Serum Vascular Endothelial Growth Factor (VEGF) Level Is An Adverse Prognostic Factor In High Risk Diffuse Large B-Cell Lymphoma (DLBCL) Patients Treated with Dose-Dense Chemoimmunotherapy and Systemic CNS Prophylaxis. Results From a Nordic Phase II Study

R-CHOEP-14 × 6 Followed by Systemic CNS Prophylaxis for Diffuse Large B-Cell Lymphoma/Follicular Lymphoma Grade 3 with Age Adjusted IPI Score 2–3: Final Results of a Nordic Lymphoma Group Phase 2 Study Including 156 Patients Aged 18–65 Years.

Exon-Based Transcriptome Profiling Reveals Genes That Have Prognostic Impact on the Survival of Young High Risk Diffuse Large B-Cell/Follicular Grade 3 Lymphoma Patients Treated with Dose-Dense Chemoimmunotherapy and CNS Prophylaxis. Results From a Nordic Lymphoma Group Phase II Study

R-CHOEP-14 X 6 Followed by Systemic CNS Prophylaxis for Diffuse Large B-Cell Lymphoma (DLBCL)/Follicular Lymphoma (FL) Grade 3 with Age Adjusted IPI Score 2–3: Preliminary Results of a Nordic Lymphoma Group (NLG) Phase 2 Study Including 160 Patients Aged 18- 64 Years

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only